Safe discontinuation of primary pneumocystis prophylaxis in Southern Indian HIV-infected patients on highly active antiretroviral therapy.
Kumarasamy
N
N
Vallabhaneni
Snigdha
S
Cecelia
Anitha J
AJ
Mayer
Kenneth H
KH
Solomon
Suniti
S
Carpenter
Charles C J
CC
Flanigan
Timothy P
TP
D000890:Anti-Infective Agents / Q000008:administration & dosage*; D044966:Anti-Retroviral Agents / Q000008:administration & dosage; D000981:Antiprotozoal Agents / Q000008:administration & dosage; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D003622:Dapsone / Q000008:administration & dosage; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007194:India; D008297:Male; D010419:Pentamidine / Q000008:administration & dosage; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage; D028761:Withholding Treatment
D000890:Anti-Infective Agents; D044966:Anti-Retroviral Agents; D000981:Antiprotozoal Agents; D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003622:Dapsone